Leqembi UK approval: BioArctic, Eisai win MHRA nod for once-monthly Alzheimer’s treatment

The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has approved a once-every-four-weeks intravenous (IV) maintenance dosing regimen for Leqembi (lecanemab) for the treatment of early Alzheimer’s disease. This development is the latest milestone in the expanding global rollout of the monoclonal antibody therapy jointly developed by BioArctic AB (publ) and its long-term partner Eisai. The new approval allows patients in the UK who have completed 18 months of biweekly IV treatment to shift to a more manageable monthly maintenance regimen at the same dose of 10 mg/kg.

Why is the UK’s approval of monthly IV Leqembi a critical step in Alzheimer’s treatment scaling?

This regulatory decision is an important step in the long-term treatment pathway for patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease who are apolipoprotein E ε4 heterozygotes or non-carriers. The monthly maintenance protocol offers a more practical administration option for both patients and healthcare systems. It also reflects the growing acceptance of disease-modifying therapies in Alzheimer’s disease that aim not just to manage symptoms, but to slow disease progression.

The once-monthly IV regimen was approved based on data from the Clarity AD Phase 3 study, which demonstrated that lecanemab significantly reduced cognitive decline and functional deterioration. The study met its primary endpoint, the Clinical Dementia Rating Sum of Boxes (CDR-SB), along with all key secondary endpoints, with statistical significance. The study formed the cornerstone of previous regulatory approvals, including those in the United States, Japan, China, and across the European Union.

How does monthly dosing change the real-world accessibility and adherence potential for Leqembi?

In August 2024, Leqembi was already approved in the United Kingdom for use in adult patients in the early stages of Alzheimer’s disease, specifically those with mild cognitive impairment or mild dementia. That approval applied to the standard biweekly IV regimen. The latest MHRA decision broadens the therapeutic scope by permitting an extended dosing interval after the initial 18-month loading phase. This evolution in dosing flexibility is seen as a key factor in reducing the logistical burden of treatment, potentially improving adherence and long-term outcomes.

Alzheimer’s disease accounts for 60 to 70 percent of all dementia cases in the United Kingdom, where approximately 982,000 people are currently estimated to be living with dementia. The growing prevalence has elevated the urgency of accessible and effective therapeutic options. Analysts believe that monthly dosing schedules such as this could help integrate anti-amyloid therapies into national treatment protocols and make them viable for broader patient populations over time.

What makes the BioArctic and Eisai partnership strategically different from other Alzheimer’s players?

Leqembi is the result of a longstanding partnership between BioArctic AB and Eisai. The antibody was developed by BioArctic based on the work of Professor Lars Lannfelt, who discovered the Arctic mutation linked to familial Alzheimer’s disease. Eisai has led clinical development and is responsible for regulatory submissions and commercialization outside the Nordic region. BioArctic retains the right to commercialize Leqembi in the Nordic countries and is actively preparing for a regional launch in collaboration with Eisai.

This latest UK approval follows a series of recent developments for Leqembi globally. In the United States, a subcutaneous version of the drug branded as Leqembi Iqlik has been approved for maintenance therapy in early Alzheimer’s disease. In September 2025, a rolling supplemental Biologics License Application was initiated with the U.S. Food and Drug Administration for subcutaneous initiation dosing. These developments indicate that Eisai and BioArctic are systematically building a full lifecycle strategy for Leqembi that spans IV induction, IV and subcutaneous maintenance, and ultimately preclinical Alzheimer’s prevention.

How is Leqembi positioned across global markets and what other trials support its approval momentum?

Leqembi is currently approved in 51 countries, and regulatory review is ongoing in nine others. In addition to the Clarity AD study, Leqembi is being evaluated in multiple trials, including the AHEAD 3-45 study in individuals with preclinical Alzheimer’s. This four-year study, which began in July 2020 and completed enrollment in October 2024, is part of a public-private partnership that includes Biogen, Eisai, and the Alzheimer’s Clinical Trial Consortium under the U.S. National Institute on Aging. Another ongoing study is Tau NexGen, run by the Dominantly Inherited Alzheimer Network Trials Unit at Washington University in St. Louis. It includes Leqembi as the anti-amyloid backbone therapy for individuals with a genetically inherited form of the disease.

What financial structure allows BioArctic to benefit from global Leqembi sales without development exposure?

From a business standpoint, BioArctic AB’s model is structured to benefit from these global developments without bearing the costs of clinical development. Under the terms of their commercialization agreement, BioArctic is eligible to receive royalties on worldwide sales and milestone payments based on commercial performance. The Swedish biotech firm has no development costs tied to Leqembi and is relying on Eisai’s global commercialization efforts to build a revenue stream from the drug. This model allows BioArctic to focus on research while leveraging Eisai’s infrastructure for regulatory and market access.

In 2014, Eisai expanded the scope of Leqembi’s commercialization by entering a joint agreement with Biogen. While Biogen’s involvement has been reduced in some operational areas over time, the foundational collaboration helped accelerate late-stage development. The ongoing regional co-commercialization with BioArctic in the Nordics also sets the stage for localized launch strategies tailored to healthcare systems in countries like Sweden, Norway, and Finland.

What other diseases and technologies are in BioArctic’s R&D pipeline beyond Alzheimer’s?

Outside of Alzheimer’s, BioArctic AB continues to advance a pipeline targeting Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and additional Alzheimer’s therapies. Several of these experimental assets leverage BioArctic’s proprietary BrainTransporter technology, which is designed to enhance antibody delivery across the blood-brain barrier. This platform is regarded as a potential differentiator in central nervous system drug development and is currently the focus of preclinical and early-stage clinical research.

How are investors reacting to the UK approval and what could move BioArctic stock next?

Investor sentiment surrounding BioArctic AB (Nasdaq Stockholm: BIOA B) has remained cautiously optimistic. Analysts tracking the stock expect incremental revenue streams to begin materializing in the Nordic region as co-commercialization proceeds. Share prices showed a modest uptick on November 13, 2025, after the MHRA announcement, reflecting renewed investor interest in the firm’s monetization prospects for Leqembi. Although market penetration depends heavily on reimbursement frameworks and physician uptake, the maintenance dosing approval is being viewed as a positive development for long-term adherence and health system integration.

As Eisai continues to file applications and receive approvals for both IV and subcutaneous formulations across major markets, BioArctic’s strategic value is increasingly tied to its out-licensed success. Analysts expect further momentum if subcutaneous initiation is approved in the United States and Europe, enabling a more flexible start-to-finish treatment continuum.

Could once-monthly maintenance dosing become the new global standard in early Alzheimer’s treatment?

This once-monthly IV option is expected to reduce healthcare delivery costs and enhance patient convenience. In publicly funded health systems such as the United Kingdom’s National Health Service, reduced infusion frequency may support broader adoption. Experts believe this maintenance regimen could become a new standard for long-term disease-modifying therapy, provided post-market real-world data reinforces the durability of efficacy observed in Clarity AD.

BioArctic has positioned itself as one of the few European biotech companies to bring a disease-modifying Alzheimer’s drug to global markets through a strategic alliance. With regulatory momentum building across regions and additional pipeline assets advancing in neurodegenerative disease, BioArctic’s future roadmap appears tightly aligned with the sector’s evolving focus on early intervention, convenience, and long-term disease management.

As the Alzheimer’s treatment landscape continues to shift from symptomatic relief to disease modification, the approval of monthly Leqembi maintenance dosing may set a new benchmark in long-term care. BioArctic and Eisai now face the challenge and opportunity of converting regulatory wins into real-world impact across global health systems.

Key takeaways: What the UK’s Leqembi maintenance approval means for Alzheimer’s care in 2025

• The United Kingdom’s MHRA has approved Leqembi (lecanemab) for once-monthly intravenous maintenance dosing in early Alzheimer’s disease.
• The approval allows patients to shift from biweekly infusions to monthly dosing after completing the initial 18-month loading phase at 10 mg/kg.
• This marks an expansion of Leqembi’s August 2024 approval in the UK, which was limited to biweekly IV dosing for ApoE ε4 heterozygotes and non-carriers.
• Leqembi is now approved in 51 countries, with regulatory reviews ongoing in nine others, and monthly IV dosing is already approved in the United States and China.
• The maintenance dosing is based on data from Eisai’s Phase 3 Clarity AD trial, which showed significant slowing of cognitive decline.
• BioArctic retains commercialization rights for Leqembi in the Nordic region and is preparing for a joint rollout with Eisai.
• A subcutaneous version branded as Leqembi Iqlik has been approved in the U.S. for maintenance use, with regulatory filings underway for initiation dosing.
• BioArctic does not bear development costs for Leqembi but receives royalties and sales-based milestones from Eisai’s global commercial activity.
• The broader Leqembi clinical program includes prevention trials such as AHEAD 3-45 and genetically targeted studies like DIAN-TU’s Tau NexGen.
• Analysts view the UK’s monthly IV approval as a meaningful step toward improving patient adherence and reducing infusion burden in national health systems.